文献速递临床试验与 GCP

脉冲电场消融与射频导管消融对阵发性室上性心动过速患者生活质量、焦虑和抑郁影响的比较:单中心、随机、单盲、标准对照试验

Comparing the effects of pulsed and radiofrequency catheter ablation on quality of life, anxiety, and depression of patients with paroxysmal supraventricular tachycardia: a single-center, randomized, single-blind, standard-controlled trial.
PubMed 文献 · Trials · 2024-02-24

该单中心随机单盲标准对照试验将50例阵发性室上性心动过速患者按1:1随机分配至脉冲电场消融组或射频导管消融组,使用SF-36和HADS在术前、术后及术后3个月评估。结果显示术后脉冲电场消融组生理功能及总体健康评分显著高于射频导管消融组,两组HADS组间无显著差异,组内随访均较术前改善。

要点

  • 术后脉冲电场消融组SF-36生理功能和总体健康评分显著高于射频导管消融组。
  • 两组HADS评分组间比较无显著差异。
  • 两组SF-36其余6个维度及HADS评分在术后3个月较术前和术后均显著改善。

核心结论

  • 脉冲电场消融可有效改善阵发性室上性心动过速患者的生活质量并减轻焦虑和抑郁。

研究设计与样本

  • 单中心、随机、单盲、标准对照试验,共50例符合入选标准的受试者按1:1随机分配至脉冲电场消融组或射频导管消融组。
  • 使用SF-36和医院焦虑抑郁量表(HADS)在术前(T0)、术后(T1)和术后3个月(T2)进行评估。
  • 采用SPSS 21.0软件通过Wilcoxon检验、Fisher精确检验和重复测量方差分析分析数据。
  • 脉冲电场消融组25例和射频导管消融组24例完成试验。

主要发现

  • T1时脉冲电场消融组SF-36生理功能(PF)评分显著高于射频导管消融组,治疗差异为5.61分(P < 0.05)。
  • T1时脉冲电场消融组SF-36总体健康(GH)评分显著高于射频导管消融组,治疗差异为18.51分(P < 0.05)。
  • 脉冲电场消融组和射频导管消融组在T2时SF-36其余6个分量表评分较T1和T0显著改善(P < 0.05),但躯体疼痛(BP)和社会功能(SF)评分除外。
  • HADS评分组间比较无显著差异(P > 0.05)。
  • 脉冲电场消融组和射频导管消融组HADS评分在T2时较T0和T1有统计学显著差异(P < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiofrequency catheter ablation (RFCA) may lead to decreased quality of life (QOL) and increased anxiety and depression in patients with paroxysmal supraventricular tachycardia (PSVT), possibly due to the lack of selectivity of the ablation tissue and the long ablation time. In recent years, pulsed field ablation (PFA) has been used for the first time in China to treat PSVT patients because of its ability to ablate abnormal tissue sites in a precise and transient manner. This study was conducted to compare the effects of PFA and RFCA on QOL and psychological symptoms of PSVT patients. METHODS: We have designed a single-center, randomized, single-blind, standard-controlled trial. A total of 50 participants who met the eligibility criteria would be randomly allocated into the PFA group or RFCA group in a 1:1 ratio. All participants were assessed using the 36-Item Short-Form Health Survey (SF-36) and the Hospital Anxiety and Depression Scale (HADS) at pre-procedure (T0), post-procedure (T1), and 3 months post-procedure (T2). The SPSS 21.0 software was used to analyze the data through Wilcoxon and Fisher's exact tests and repeated measures ANOVA. RESULTS: Twenty-five in the PFA group and 24 in the RFCA group completed the trial. SF-36: (1) Between-group comparison: At T1, PFA group had significantly higher SF-36 scores on physiological function (PF) and general health (GH) than RFCA group, with a treatment difference of 5.61 points and 18.51 points(P < 0.05). (2) Within-group comparison: We found that in the PFA and RFCA groups, T2 showed significant improvement in the remaining 6 subscales of the SF-36 scale compared to T1 and T0 (P < 0.05), except for body pain (BP) and social function (SF) scores. HADS: (1) Between-group comparison: no significant difference (P > 0.05). (2) Within-group comparison: The HADS scores of the PFA and RFCA groups were statistically significant at T2 compared to T0 and T1 (P < 0.05). CONCLUSIONS: Our study provided new and meaningful evidence that PFA was effective in significantly improving QOL and decreasing anxiety and depression in PFA patients. TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2200060272.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Du Y, Ma S, Yue P, et al. Comparing the effects of pulsed and radiofrequency catheter ablation on quality of life, anxiety, and depression of patients with paroxysmal supraventricular tachycardia: a single-center, randomized, single-blind, standard-controlled trial. Trials. 2024. PMID: 38402192. doi:10.1186/s13063-024-07971-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。